256 related articles for article (PubMed ID: 34588146)
1. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
2. Timing of High-Dose-Rate Brachytherapy With External Beam Radiation Therapy in Patients With Intermediate- and High-Risk Localized Prostate Cancer and Its Effects on Toxicity and Quality of Life: A Randomized Controlled Trial (THEPCA).
Choudhury M; Thomas SS; Cain A; Palvai S; Nageshwaran S; Zhang J; Hayden K; Cain A; Hoskin P; Ahmed I
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):90-99. PubMed ID: 38163520
[TBL] [Abstract][Full Text] [Related]
3. F-SHARP: a Phase I/II trial of focal salvage high-dose-rate brachytherapy for Radiorecurrent prostate cancer.
Solanki AA; Yoo RK; Adams W; Davicioni E; Mysz ML; Shea S; Gupta GN; Showalter T; Garant A; Hentz C; Farooq A; Baldea K; Small W; Harkenrider MM
BJU Int; 2024 Feb; 133(2):188-196. PubMed ID: 37562825
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (≥100 cc) Glands.
Hurwitz JC; Haas J; Mendez C; Sanchez A; Santos VF; Akerman M; Carpenter T; Tam M; Katz A; Corcoran A; Mahadevan A; Taneja SS; Lepor H; Lischalk JW
Pract Radiat Oncol; 2024; 14(3):241-251. PubMed ID: 37984713
[TBL] [Abstract][Full Text] [Related]
5. Virtual HDR CyberKnife SBRT for Localized Prostatic Carcinoma: 5-Year Disease-Free Survival and Toxicity Observations.
Fuller DB; Naitoh J; Mardirossian G
Front Oncol; 2014; 4():321. PubMed ID: 25505732
[TBL] [Abstract][Full Text] [Related]
6. Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes.
Carrasquilla M; Sholklapper T; Pepin AN; Hodgins N; Lei S; Rashid A; Danner M; Zwart A; Bolanos G; Ayoob M; Yung T; Aghdam N; Collins B; Suy S; Kumar D; Hankins R; Kowalczyk K; Dawson N; Collins S
Front Oncol; 2023; 13():1240939. PubMed ID: 38074646
[TBL] [Abstract][Full Text] [Related]
7. High-risk prostate cancer treated with a stereotactic body radiation therapy boost following pelvic nodal irradiation.
Lischalk JW; Akerman M; Repka MC; Sanchez A; Mendez C; Santos VF; Carpenter T; Wise D; Corcoran A; Lepor H; Katz A; Haas JA
Front Oncol; 2024; 14():1325200. PubMed ID: 38410097
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1 Trial of Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer After Brachytherapy.
Patel KR; Rydzewski NR; Schott E; Cooley-Zgela T; Ning H; Cheng J; Salerno K; Huang EP; Lindenberg L; Mena E; Choyke P; Turkbey B; Citrin DE
Int J Radiat Oncol Biol Phys; 2024 Feb; ():. PubMed ID: 38428681
[TBL] [Abstract][Full Text] [Related]
9. High-dose-rate brachytherapy as monotherapy versus as boost in unfavorable intermediate-risk localized prostate cancer: A matched-pair analysis.
Willen BD; Salari K; Zureick AH; Lang D; Ye H; Marvin K; Nandalur SR; Krauss DJ
Brachytherapy; 2023; 22(5):571-579. PubMed ID: 37328337
[TBL] [Abstract][Full Text] [Related]
10. Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center.
Leroy T; Lacornerie T; Bogart E; Nickers P; Lartigau E; Pasquier D
Radiat Oncol; 2017 Jun; 12(1):95. PubMed ID: 28599663
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial.
Wages NA; Sanders JC; Smith A; Wood S; Anscher MS; Varhegyi N; Krupski TL; Harris TJ; Showalter TN
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1254-1262. PubMed ID: 33227441
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity.
Ugurluer G; Atalar B; Zoto Mustafayev T; Gungor G; Aydin G; Sengoz M; Abacioglu U; Tuna MB; Kural AR; Ozyar E
Br J Radiol; 2021 Jan; 94(1117):20200696. PubMed ID: 33095670
[TBL] [Abstract][Full Text] [Related]
14. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809.
Hurwitz MD; Halabi S; Archer L; McGinnis LS; Kuettel MR; DiBiase SJ; Small EJ
Cancer; 2011 Dec; 117(24):5579-88. PubMed ID: 22535500
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Aibe N; Shimizu D; Kimoto T; Yamada K; Ueno A; Matsugasumi T; Yamada Y; Shiraishi T; Fujihara A; Okihara K; Yoshida K; Nakamura S
Sci Rep; 2021 Mar; 11(1):6165. PubMed ID: 33731856
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.
Patel KR; Rydzewski NR; Schott E; Cooley-Zgela T; Ning H; Cheng J; Salerno K; Huang EP; Pinto PA; Lindenberg L; Mena E; Choyke P; Turkbey B; Citrin DE
Pract Radiat Oncol; 2023; 13(6):540-550. PubMed ID: 37442430
[TBL] [Abstract][Full Text] [Related]
17. Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: 5-Year Toxicity and Biochemical Recurrence Results From a Prospective Trial.
Maas JA; Dobelbower MC; Yang ES; Clark GM; Jacob R; Kim RY; Cardan RA; Popple R; Nix JW; Rais-Bahrami S; Fiveash JB; McDonald AM
Pract Radiat Oncol; 2023; 13(5):466-474. PubMed ID: 37268193
[TBL] [Abstract][Full Text] [Related]
18. Prostate hypofractionated radiotherapy (62Gy at 3.1Gy per fraction) with injection of hyaluronic acid: final results of the RPAH1 study.
Chapet O; Udrescu C; Bin S; Decullier E; Fenoglietto P; Beneux A; Segui B; Enachescu C; Gaudioz S; Ruffion A; Azria D
Br J Radiol; 2021 Aug; 94(1124):20210242. PubMed ID: 34282946
[TBL] [Abstract][Full Text] [Related]
19. Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT).
Glicksman RM; Loblaw A; Morton G; Vesprini D; Szumacher E; Chung HT; Chu W; Liu SK; Tseng CL; Correa R; Deabreu A; Mamedov A; Zhang L; Cheung P
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):100-109. PubMed ID: 37979707
[TBL] [Abstract][Full Text] [Related]
20. The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study.
Pasquier D; Lacornerie T; Supiot S; Pommier P; Quivrin M; Simon JM; Loos G; Meyer E; Calais G; Peiffert D; Vandendorpe B; Aymes E; Leguillette C; Brihoum M; Nenan S; Cormier L; Le Deley MC; Lartigau EF
Eur Urol Oncol; 2023 Aug; 6(4):399-405. PubMed ID: 36754722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
